🇺🇸 FDA
Patent

US 10273307

Humanized anti-CD134 (OX40) antibodies and uses thereof

granted A61PA61P35/00A61P37/04

Quick answer

US patent 10273307 (Humanized anti-CD134 (OX40) antibodies and uses thereof) held by Biocerox Products B.V. expires Mon Apr 25 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Biocerox Products B.V.
Grant date
Tue Apr 30 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Apr 25 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
17
CPC classes
A61P, A61P35/00, A61P37/04